Biosimilar Antibodies

Ontuxizumab (MORAb-004) is a humanized IgG1 kappa monoclonal antibody targeting endosialin (also known as TEM-1 or CD248). This antibody exhibits antitumor properties by specifically binding to endosialin, a protein predominantly expressed in tumor vasculature and certain tumor stromal cells. Ontuxizumab is utilized primarily in cancer research to investigate its therapeutic potential and mechanism of action in tumor inhibition.

The Anti-EphB2 Antibody is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets the EphB2 receptor, a member of the Eph family of receptor tyrosine kinases involved in developmental processes and disease states such as cancer. This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, with an approximate molecular weight of 150 kDa. For experimental control purposes, the recommended isotype control is Human IgG1 kappa, Isotype Control. This antibody is suitable for use in various immunological assays to study EphB2 function and expression.

Odesivimab is a human monoclonal antibody specifically designed to target the glycoprotein of the Ebola virus. It exhibits a high affinity for the recombinant histidine-tagged Makona strain Ebola virus glycoprotein ectodomain, with a dissociation constant (K_D) of 7.74 nM. This antibody is ideal for use in research focused on Ebola virus infection, aiding in the study of viral entry mechanisms and immune response.

Neihulizumab (ALTB-168) functions as an agonistic antibody targeting the immune checkpoint receptor CD162, also known as PSGL-1. By binding to this receptor, Neihulizumab effectively mediates the downregulation of activated T-cells. This antibody is primarily utilized in research focusing on steroid-refractory acute graft-versus-host disease (SR-aGVHD), as well as studies related to psoriasis, psoriatic arthritis, and ulcerative colitis. Its unique mechanism and specificity make it a valuable tool in the investigation of immune response modulation in these conditions.

Adakitug (BMS-986253) is a recombinant human monoclonal antibody expressed in Chinese Hamster Ovary (CHO) cells, specifically designed to target CXCL8/IL-8. This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, with a predicted molecular weight of 144.94 kDa. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended.

Cabiralizumab (FPA 008) is a monoclonal antibody targeting CSF1R (Colony Stimulating Factor 1 Receptor), designed to modulate the immune system by enhancing T cell infiltration and promoting antitumor immune responses. This antibody effectively inhibits the activation of osteoclasts, thereby preventing bone destruction, making it a valuable tool in the study of rheumatoid arthritis. Additionally, Cabiralizumab has been utilized in combination with Nivolumab in the exploration of therapeutic strategies for lung cancer, highlighting its potential in oncology research settings.

Talacotuzumab (JNJ 56022473; CSL 362) is a fully humanized IgG1 monoclonal antibody engineered to neutralize CD123. It exhibits dissociation constants (K_Ds) of 0.43 nM for CD123, 188 nM for CD32b/c, 46 nM for CD16-158F, and 16.8 nM for CD16-158V, indicating high specificity and affinity for these targets. The antibody effectively inhibits interleukin-3 (IL-3) binding to CD123, thereby blocking IL-3 mediated signaling pathways in targeted cells. The Fc region of Talacotuzumab has been specifically mutated to enhance its affinity for CD16 (FcγRIIIa), which significantly amplifies its capability to mediate antibody-dependent cell-mediated cytotoxicity (ADCC). This modification enhances its therapeutic potential, particularly in oncology applications. In vivo studies demonstrate that Talacotuzumab significantly reduces leukemic cell proliferation in acute myeloid leukemia (AML) xenograft mouse models, highlighting its potential as a therapeutic agent in hematological malignancies.

The Anti-MSPR/RON/CD136 Antibody (H5B14) is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting the MSPR/RON/CD136 antigen. This antibody is constructed with a human IgG1 heavy chain and a human kappa light chain, exhibiting a predicted molecular weight of 156.7 kDa. For experimental control purposes, the Human IgG1 kappa, Isotype Control should be utilized as the isotype control for this antibody. This product is essential for researchers focusing on the biological pathways and disease associations involving the MSPR/RON/CD136 protein.

Ixotatug is a monoclonal antibody designed to selectively target human Claudin-6 (CLDN6), a tight junction protein frequently overexpressed in various tumor types. By binding to CLDN6, Ixotatug disrupts critical signaling pathways within tumor cells, thereby exerting potent antitumor effects. This antibody is particularly valuable for research focused on the pathophysiology and therapeutic targeting of CLDN6-associated cancers.

The Anti-pan-Glypican Antibody (HS20) is a human monoclonal antibody of the IgG1, κ subclass, specifically designed to target human pan-Glypican. For accurate isotype control in experimental setups, it is recommended to use Mouse IgG1 kappa Isotype Control. This antibody is suitable for a range of research applications, providing specificity and reliability in targeting the pan-Glypican, which is implicated in various cellular processes and disease states.

Riltovetbart is a canine-derived monoclonal antibody of the IgG2 κ class, specifically targeting interleukin-13 (IL13) in the Canlupfam species. This antibody is engineered for high specificity and affinity, making it an ideal tool for detailed studies of IL13's role in immune responses and potential therapeutic interventions in related canine disorders.

The Anti-MMP9 Antibody is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target MMP9 (Matrix Metallopeptidase 9). This antibody is constructed from a human IgG1 heavy chain and a human kappa light chain, exhibiting a predicted molecular weight of 144.76 kDa. For isotype control, researchers should use the Human IgG2 kappa, Isotype Control, which serves as an appropriate reference for assessing the specificity and binding characteristics of the Anti-MMP9 Antibody in various experimental setups. This product is suitable for a range of applications in the study of enzyme regulation and tissue remodeling processes.

Naptumomab is a fusion protein incorporating a tumor-targeting superantigen (TTS), designed to enhance the immune system's ability to detect and eliminate tumor cells. This biologic is particularly utilized in research focused on refractory solid tumors, including renal cell carcinoma, providing a valuable tool for investigations into novel cancer immunotherapies.

Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody engineered to specifically target and bind to tumor necrosis factor-alpha (TNF-α). By binding to TNF-α, Infliximab inhibits its interaction with its receptors, TNFR1 and TNFR2, effectively modulating the inflammatory response. This antibody is widely utilized in the study of autoimmune and chronic inflammatory diseases, as well as in research focused on diabetic neuropathy. Infliximab serves as a critical tool in elucidating the pathophysiological mechanisms underlying these conditions and in the development of therapeutic strategies.

FR104 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target CD28. This antibody consists of a human IgG2 heavy chain and a human kappa light chain, with an estimated molecular weight of 145 kDa. For experimental control purposes, Human IgG2 kappa, Isotype Control is recommended.

Catumaxomab is a trifunctional IgG2 antibody engineered from mouse and rat heavy and light chains. This antibody exhibits specific binding to human epithelial cell adhesion molecule (EpCAM) and the T-cell receptor CD3. Additionally, the Fc region of Catumaxomab demonstrates affinity for Fc gamma receptors FcγR1 (CD64), FcγRIIA (CD32a), and FcγRIII (CD16). Due to its unique binding properties, Catumaxomab is particularly valuable in the study of epithelial cancers, serving as a potent tool in anti-tumor research applications.

Xentuzumab (BI836845) is a recombinant human monoclonal antibody specifically designed to target and neutralize the insulin-like growth factors IGF1 and IGF2. By binding to these ligands, Xentuzumab effectively inhibits their role in promoting cellular growth and proliferation. Additionally, this antibody suppresses the activation of AKT, a critical kinase in the PI3K/AKT signaling pathway, further impeding oncogenic signaling. This dual mechanism of action makes Xentuzumab a valuable tool in research focused on cancer biology, particularly in studies exploring the regulation of growth factor-mediated signal transduction and its impact on cellular behaviors.

Olaratumab (IMC-3G3; LY3012207) is a human monoclonal IgG1 antibody targeting the platelet-derived growth factor receptor alpha (PDGFRα). This antibody exhibits potent antitumor activity by inhibiting the PDGFRα pathway, which is implicated in various forms of cancer cell proliferation and tumor growth. Olaratumab is utilized primarily in research focused on the development and therapeutic intervention of malignancies where PDGFRα plays a critical role.

Precemtabart is a human monoclonal antibody of the IgG1κ subtype that specifically targets CEACAM5. For experimental control purposes, it is recommended to use Human IgG1 kappa as the isotype control.

The Anti-CD1a Antibody (OKT-6) is a chimeric mouse monoclonal antibody of the IgG1 subtype, specifically designed to target human CD1a. For optimal experimental control, it is recommended to use Mouse IgG1 kappa as the isotype control. This product is ideal for research applications requiring precise targeting of the CD1a molecule.

Elipovimab is a potent, broadly neutralizing antibody designed for the targeted elimination of cells infected with HIV-1. This antibody binds specifically to the HIV-1 envelope protein, facilitating the recognition and destruction of infected cells by the immune system. Elipovimab's broad neutralizing capability makes it a valuable tool for research into the mechanisms of HIV infection and potential therapeutic interventions.

Nisevokitug (NIS-793) is a recombinant human IgG2λ monoclonal antibody specifically designed to target and neutralize transforming growth factor-beta (TGF-β), encompassing both TGFB1 and TGFB2 isoforms. This antibody is produced in CHO-K1 cells, ensuring high fidelity and consistency in performance. Nisevokitug is utilized primarily in research focused on the modulation of TGF-β activity, which is crucial in various physiological and pathological processes including cell growth, inflammation, and fibrosis.

Fletikumab (NNC0109-0012) is a monoclonal antibody specifically designed to target interleukin-20 (IL-20). This antibody is utilized primarily in the study of inflammatory processes, with a focus on conditions such as rheumatoid arthritis. Fletikumab serves as a valuable tool in elucidating the role of IL-20 in inflammatory pathways and may contribute to the development of therapeutic strategies for managing rheumatoid arthritis and related inflammatory disorders.

Tusamitamab is an IgG1 monoclonal antibody specifically designed to target CEACAM5, a cell surface glycoprotein implicated in various cellular processes and tumor progression. This antibody serves as a foundational component in the synthesis of the antibody-drug conjugate (ADC) Tusamitamab ravtansine (SAR408701), highlighting its utility in targeted cancer therapy research.

Tucotuzumab is a recombinant IgG1 monoclonal antibody that specifically targets the human epithelial cell adhesion molecule (EpCAM). This antibody is engineered to conjugate two molecules of interleukin-2 (IL-2), enhancing its therapeutic potential. Tucotuzumab acts both as an immunosuppressant and an anti-tumor agent, making it a valuable tool for research in cancer immunotherapy and the study of epithelial cell biology.

Oleclumab (MEDI9447) is a human IgG1λ monoclonal antibody designed to selectively target and inhibit the exonuclease activity of CD73, an extracellular enzyme. By modulating the activity of CD73, Oleclumab influences the composition of bone marrow and lymphoid infiltrating leukocyte populations within the tumor microenvironment, demonstrating significant anti-tumor activity. This antibody is pivotal in studies focused on tumor immunology and the development of cancer immunotherapies.

Luveltamab is a human IgG1 κ monoclonal antibody targeting the folate receptor alpha (FOLR1). For experimental control purposes, it is recommended to use Human IgG1 kappa as an isotype control.

Geptanolimab (CBT-501) is a humanized IgG4 kappa monoclonal antibody that targets the programmed death-1 (PD-1) receptor. This antibody functions by competitively inhibiting the interaction between PD-1 and its ligands PD-L1 and PD-L2, thereby modulating immune responses. Geptanolimab is primarily utilized in cancer research to investigate the therapeutic potential of PD-1 blockade in oncology.

Remtolumab (ABT-122) is a dual-variable domain immunoglobulin specifically engineered to neutralize tumor necrosis factor α (TNFα) and interleukin-17A (IL-17A). This biologic exhibits potent dual inhibition, effectively targeting both cytokines implicated in inflammatory processes. It is particularly useful in research focused on rheumatoid arthritis (RA), providing a valuable tool for investigating the pathophysiology and potential therapeutic interventions for this condition.

Sigvotatug is a human IgG1 κ monoclonal antibody targeting the integrin subunit beta 6 (ITGB6). For experimental control purposes, it is recommended to use Human IgG1 kappa as an isotype control.

Vandortuzumab is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target STEAP1. This antibody comprises a human IgG1 type heavy chain and a human kappa type light chain, resulting in a predicted molecular weight of 148.74 kDa. For experimental control purposes, the appropriate isotype control is Human IgG1 kappa.

Siplizumab (MEDI-507) is a humanized IgG1 monoclonal antibody that targets CD2, a cell surface antigen predominantly expressed on T cells. This antibody functions by depleting T cells, reducing their activation, and inhibiting their proliferation. Additionally, Siplizumab promotes the enrichment of naïve and bona fide regulatory T cells. It is utilized primarily in research focused on immunological tolerance, autoimmunity, and transplantation immunology.

Pimivalimab (JTX-4014) functions as an inhibitor of the programmed cell death protein 1 (PD-1), a critical immune checkpoint receptor involved in downregulating immune responses and promoting self-tolerance by suppressing T cell inflammatory activity. This monoclonal antibody is specifically designed for the investigation of solid tumors in a research setting, providing a valuable tool for the study of immune checkpoint pathways and their role in cancer immunotherapy.

Onartuzumab (MetMAb) is a humanized, affinity-matured monovalent monoclonal antibody specifically targeting the MET receptor. This antibody effectively inhibits hepatocyte growth factor (HGF) binding, thereby preventing receptor phosphorylation and downstream signaling. Characterized by pharmacokinetics akin to those of typical antibodies, Onartuzumab demonstrates significant antitumor activity, making it a valuable tool for research in cancer biology and therapeutic development.

Penpulimab is a monoclonal antibody featuring an IgG1 backbone and is designed to target the PD-1 receptor, exhibiting potent antitumor activities. This antibody interferes with the PD-1 pathway, a critical immune checkpoint that inhibits T-cell activity, thus enhancing the immune system's ability to attack tumor cells. Penpulimab is primarily utilized in oncological research to investigate immune response modulation in various cancer models.

Eculizumab is a long-acting, humanized monoclonal antibody that specifically targets complement component C5. By inhibiting the cleavage of C5 into C5a and C5b, Eculizumab effectively prevents the activation of the terminal complement system, including the formation of the membrane attack complex (MAC). This antibody is particularly useful in research focused on hemolysis and other conditions related to complement system dysregulation.

The Anti-F3/Factor III/Tissue Factor/CD142 Antibody is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. This antibody specifically targets the F3 protein, also known as Factor III, Tissue Factor, or CD142, which plays a critical role in the initiation of blood coagulation. The antibody is comprised of a human IgG4 subclass heavy chain with an SP variant and a human kappa light chain. It exhibits a predicted molecular weight of approximately 150 kDa. For experimental control purposes, the recommended isotype control is Human IgG4 kappa. This product is essential for research in hematology, particularly in studies involving coagulation pathways and cardiovascular disease mechanisms.

BI-1808 is a human IgG1 monoclonal antibody designed to selectively target TNFR2 (Tumor Necrosis Factor Receptor 2). It functions by inhibiting the interaction between TNFR2 and its ligand TNF-α. This antibody facilitates the FcγR-dependent depletion of regulatory T cells (Tregs) and promotes the expansion of CD8+ T cells within the tumor microenvironment. BI-1808 is utilized in research focused on modulating immune responses and studying the mechanisms of immune evasion in cancer.

Nurulimab (BCD-145) is a human monoclonal antibody that targets cytotoxic T lymphocyte antigen-4 (CTLA-4). This antibody is specifically designed for use in melanoma research, where it can help investigate the role of CTLA-4 in tumor immunity and potential therapeutic interventions.

The Anti-CD326/EpCAM Antibody (Ber-EP4) is a chimeric mouse monoclonal antibody of the IgG1 κ isotype, specifically designed to target human CD326, also known as Epithelial Cell Adhesion Molecule (EpCAM). This antibody has been engineered for high specificity and affinity toward the EpCAM antigen, a cell surface protein predominantly expressed in epithelial tissues and associated with cell signaling, migration, proliferation, and differentiation. It is commonly utilized in research focusing on cancer biology, particularly in studies involving carcinomas where EpCAM is often overexpressed. For accurate isotype control in experimental assays, the use of Mouse IgG1 kappa Isotype Control is recommended to ensure specificity and consistency in results.

Cergutuzumab is a fully human monoclonal antibody of the IgG1 isotype, specifically designed to target CEACAM5, a cell surface glycoprotein implicated in various cellular processes including cell adhesion and signaling. The recommended isotype control for experiments involving Cergutuzumab is Human IgG1 kappa, serving as a critical component for assessing the specificity and background activity of the antibody in various assays.

Ebronucimab (AK102) is a recombinant IgG1-λ2 monoclonal antibody specifically designed to target Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9). This antibody is produced in Chinese Hamster Ovary (CHO) DG44 cells, ensuring high fidelity and consistency in antibody structure and function. Ebronucimab binds to PCSK9, inhibiting its ability to interact with the low-density lipoprotein receptor (LDLR), thereby modulating cholesterol metabolism. This makes it a valuable tool for research in cardiovascular diseases, lipid metabolism, and therapeutic development.

Tenatumomab (ST2146) is a murine monoclonal antibody developed to target tenascin-C, a large extracellular glycoprotein frequently overexpressed in various cancers. This antibody has demonstrated utility in advanced diagnostic and therapeutic techniques, including Pretargeted Antibody Guided Radioimmunotherapy (PAGRIT). Through PAGRIT, as well as direct labeling with 131-Iodine, tenatumomab facilitates the precise delivery of radionuclides to tumor sites, enhancing the specificity and efficacy of cancer imaging and treatment modalities.

Zamerovimab (CTB011) is a humanized IgG1κ monoclonal antibody designed to specifically bind to non-overlapping epitopes on the rabies virus (RABV) glycoprotein, focusing on residues at and near antigenic site III. This targeted binding capability makes Zamerovimab an essential tool for research in rabies, facilitating detailed studies on viral mechanisms and potential therapeutic interventions.

Enlonstobart is a human monoclonal antibody of the immunoglobulin G4-kappa subtype, specifically targeting the programmed cell death protein 1 (PD-1). This antibody acts as an immunostimulant and possesses antineoplastic properties, making it suitable for research in cancer immunotherapy and immune response modulation.

Mirikizumab (LY3074828) is a humanized IgG4 monoclonal antibody specifically designed to target the p19 subunit of interleukin 23 (IL-23). This antibody demonstrates high affinity binding to IL-23 in both human and monkey models, with dissociation constants (Kd) of 21 pM and 55 pM, respectively. By selectively inhibiting the interaction between IL-23 and its receptor IL-23R, Mirikizumab effectively modulates the immune response. This mechanism of action suggests its utility in exploring therapeutic avenues for inflammatory bowel diseases such as ulcerative colitis and Crohn's disease in research settings.

Orilanolimab (SYNT001) is a humanized, de-immunized monoclonal antibody designed to block the neonatal Fc receptor (FcRn). By inhibiting the interaction between FcRn and the Fc portion of IgG molecules, Orilanolimab effectively impedes the activation of immune complexes (IC) mediated by FcRn. This action disrupts key pathways involved in IgG homeostasis, as well as innate and adaptive immune responses. This antibody is pivotal for research focused on the modulation of immune functions and the therapeutic regulation of antibody-mediated diseases.

BMS-986178 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target TNFRSF4, also known as OX40 or CD134. This antibody comprises a human IgG1 heavy chain and a human kappa light chain, with an estimated molecular weight of 150 kDa. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended.